SolasCure

Our CTO Bela Kelety is in Cologne for the Interdisciplinary Wound Congress (IWC)! Wound care remains a major global health challenge, and this year’s congress focuses on new technologies and sustainable therapy approaches, highlighting innovations which aim to shape the future of the field. Get in touch! Learn how SolasCure is developing Aurase Wound Gel, a hydrogel that releases tarumase—a recombinant enzyme derived from medical maggots—to transform chronic wound care with what aims to be a fast, effective, and easy-to-use solution adaptable to all wound care settings ➡️ https://lnkd.in/eWGjRw2d #Wounds #ChronicWounds #Healthcare

𝐖𝐨𝐮𝐧𝐝 𝐂𝐚𝐫𝐞 𝐕𝐨𝐢𝐜𝐞𝐬 is a new blog series by members of our senior leadership team. Leveraging decades of industry experience, each will outline how they and SolasCure are working to make a real difference in the treatment of chronic wounds. The series will explore a wide range of topics across wound care, from the technology and history behind our enzyme-containing hydrogel to the current challenges faced by clinicians, nurses and most importantly, patients. Kicking off the series is CEO, Lee Harle, in his blog "Why the Battle Against Chronic Wounds is Worth Fighting". Chronic wounds are common, painful and costly - significantly impacting patients’ lives. Yet despite advances in technology, chronic wound healing rates remain largely unchanged over recent decades. In this thought-provoking opener, Lee explores the factors that have hindered innovation and progress in wound care and outlines the challenges which he and the team at SolasCure are committed to tackling. Read the full blog here: https://lnkd.in/ePk74Cbf #WoundCare #ChronicWounds

November has been a busy month for our team, from announcing an exciting US military collaboration to attending conferences across the UK and Europe. 🗨️Our Chairman of the Board, Andy Weymann, shares his takeaways from one of this month’s highlights, #BioEurope 2024: “Events like BIO Europe are invaluable for connecting with industry leaders, and the partneringOne platform proved especially helpful in navigating over 5,500 attendees. The event was impressively organised, meeting opportunities were plenty available and many service providers were there. The keynotes from seasoned dealmakers, including company representatives and venture capitalists, provided particularly insightful perspectives.” #ChronicWounds #Innovation

We’re kicking off the week in London for today’s Investival Showcase, hosted by LSX - partnering for Life Science eXecutives! As part of Europe’s largest dedicated healthcare investment week, today marks the beginning of an insightful few days filled with dialogue, debate and deal making. Arrange a meeting with CEO Lee Harle and CFO Oliver Schofield to learn more about how SolasCure is developing Aurase Wound Gel to transform chronic wound care, with the goal of offering a fast, effective, and easy-to-use solution adaptable to all wound care settings ➡️ https://lnkd.in/eEvptdh9 #ChronicWounds #WoundCare #Investival

This week, David Fairlamb, our Chief Development Officer, and Professor David Goldsmith, our Senior Medical Advisor, are attending the annual Wounds UK conference, hosted at the Harrogate Convention Centre. The focus of the conference is Integrated Strategies and Solutions for Quality Outcomes, featuring the latest clinical opinions, research, and policies from across the UK. SolasCure is developing Aurase Wound Gel to transform chronic wound care, with the goal of offering a fast, effective, and easy-to-use solution adaptable to all wound care settings. Our team will be on the floor asking conference attendees to 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞 𝐢𝐧 𝐨𝐮𝐫 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐏𝐫𝐚𝐜𝐭𝐢𝐭𝐢𝐨𝐧𝐞𝐫 𝐒𝐮𝐫𝐯𝐞𝐲, where we aim to gain an even better understanding of the routine clinical practices currently involved in the debridement of chronic wounds, with a view to making Aurase Wound Gel as practical as possible for those on the front lines of treating chronic wounds. Arrange a meeting with David Fairlamb and Professor David Goldsmith to learn more ➡️ https://lnkd.in/dZpfkjY #WoundCare #ChronicWounds #WUK24 #wearewounds

Our CTO Bela Kelety is in Düsseldorf, Germany for MEDICA - Leading International Trade Fair, one of the largest B2B fairs in the world, showcasing a wide range of products across the medical technology and healthcare sectors.   Please get in touch if you’d like to discover how SolasCure is developing Aurase Wound Gel, which aims to effectively debride and return wounds to healing - with the goal of offering a fast, effective, and easy-to-use solution for all wound care settings. Visit ➡️ https://lnkd.in/eWGjRw2d   #MEDICA #WoundCare #Healthcare

📢News update We are thrilled to announce a research collaboration with the U.S. Army Institute of Surgical Research to evaluate our investigational product, Aurase Wound Gel, for managing combat wounds. Aurase Wound Gel is a hydrogel releasing tarumase, a recombinant enzyme derived from medical maggots. Two non-clinical projects will examine its enzymatic debridement potential to reduce wound biofilm and bioburden in prolonged field care scenarios, specifically targeting combat-relevant persistent strains of Pseudomonas aeruginosa and MRSA. Both pathogens complicate wound care by producing toxins and enzymes that damage tissue. Read the full press release here ➡️ https://lnkd.in/eVvb59hu #WoundCare #Hydrogel #ChronicInfections #Biofilm

BIO Europe 2024 is in full swing over in Stockholm! Now in its 30th year of fostering partnerships, this year the programme spotlights Sweden’s collaborative approach to biotech and explores the latest trends, challenges, and opportunities in life sciences. Arrange a meeting with Andy Weymann, our Chairman of the Board, to learn more about Aurase Wound Gel—SolasCure’s investigational product seeking to transform chronic wound care worldwide. Aurase Wound Gel aims to offer a fast, effective, and easy-to-use solution adaptable to all wound care settings. Get in touch via the partnering platform➡️ https://lnkd.in/eST-rXbF #BIOEurope2024 #WoundCare #Innovation

BIO Europe 2024 is in full swing over in Stockholm! Now in its 30th year of fostering partnerships, this year the programme spotlights Sweden’s collaborative approach to biotech and explores the latest trends, challenges, and opportunities in life sciences. Arrange a meeting with Andy Weymann, our Chairman of the Board, to learn more about Aurase Wound Gel—SolasCure’s investigational product seeking to transform chronic wound care worldwide. Aurase Wound Gel aims to offer a fast, effective, and easy-to-use solution adaptable to all wound care settings. Get in touch via the partnering platform➡️ https://lnkd.in/eST-rXbF #BIOEurope2024 #WoundCare #Innovation

Next month, join our Chairman of the Board, Andy Weymann, in Sweden for #BIOEurope 2024, celebrating 30 years of fostering partnerships in the life science ecosystem.   As Europe’s premier partnering event, BIOEurope will gather over 5,500 attendees from more than 2,800 companies across 60+ countries to drive dealmaking and innovation.   SolasCure seeks to transform chronic wound care worldwide with Aurase Wound Gel, which aims to effectively debride and return wounds to healing, and offer a fast, effective, and easy-to-use solution for all wound treatment settings.   To learn more or schedule a one-on-one meeting, visit our website or get in touch via the partnering platform ➡️ https://lnkd.in/dCbGGu3z   #BIOEurope2024 #WoundCare #Innovation